Clinical and epidemiological aspects of corpus uteri cancer in the context of prevention of recurrent endometrial hyperplasia


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To analyze trends in the incidence of corpus uteri cancer (CUC) in the Omsk Region in 2002-2018 to prioritize cancer prevention in patients with endometrial hyperplasia (EH). Material and methods. A continuous descriptive observational retrospective epidemiological study of CUC incidence rates was conducted using official statistics. Results. There was a moderate tendency for higher CUC incidence rates in the region (Growth rate (Gr) = +1.8%; p < 0.001) and in the Russian Federation (Gr = +1.7%; p <0.001). The highest proportion was 32.3% of women aged 60-69 years. There was a moderate tendency for increased CUC incidence rates among 30 to 39 year olds and a marked tendency for higher ones in women aged 35-39 years (Gr = +5.6%; p <0.05). A rationale was provided for an integrated approach to managing patients with EH in the context of prevention of the recurrent disease. Conclusion. It was established that the Omsk Region showed a rise in CUC incidence and a tendency for patients with th is disease to become younger. One of the measures to reduce the risk of HE recurrence and progression is the need for a preventive therapy cycle, by taking into account endometrial morphological control.

全文:

受限制的访问

作者简介

Tatiana Klinyshkova

Omsk State Medical University Ministry of Health of Russia

Email: klin_tatyana@mail.ru
MD, Full Professor, Professor of the Graduate Education Department of obstetrics and gynecology 644043 Russia, Omsk, Lenin Str., 12

Denis Turchaninov

Omsk State Medical University Ministry of Health of Russia

Email: omskgsen@yandex.ru
MD, Full Professor, Head of the Department of Hygiene and Nutrition 644043 Russia, Omsk, Lenin Str., 12

Natalia Frolova

Railway Clinical Hospital at the Omsk Passenger Station OAO "RZhD"

Email: nbfrolova@yandex.ru
PhD, Head of gynecological Department 644005 Russia, Omsk, Karbysheva str., 41

参考

  1. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. 250 e
  2. World Health Organization: GLOBOCAN 2018. Cancer Today -IARC. https://gco.iarc.fr/today/home
  3. Думановская М.Р., Чернуха Г.Е., Асатурова А.В., Коган Е.А. Частота выявления и структура гиперплазии эндометрия в различные возрастные периоды. Акушерство и гинекология. 2015; 3: 40-4.
  4. Orbo A., Vereide A., Arnes M., Pettersen I., Straume B. Levonorgestrel-impregnated intrauterine device as treatment forendometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014; 21(4): 477-86. doi: 10.1111/1471-0528.12499.
  5. Marnach M.L., Butler K.A., Henry M.R., Hutz C.E., Langstraat C.L., Lohse C.M., Casey P.M. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia. J Womens Health (Larchmt). 2017; 26(4): 368-73. doi: 10.1089/jwh.2016.5774.
  6. El Behery M.M., Saleh H.S., Ibrahiem M.A., KamalE.M., Kassem G.A., Mohamed Mel S. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. Reprod Sci. 2015; 22(3): 329-34. doi: 10.1177/1933719114542014
  7. Abu Hashim H., Zayed A., Ghayaty E., El Rakhawy M. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial. J Gynecol Oncol. 2013; 24(2): 128-34. doi: 10.3802/jgo.2013.24.2.128.
  8. Gallos I.D., Shehmar M., Thangaratinam S., Papapostolou T.K., Coomarasamy A., Gupta J.K. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Аm J Obstet Gynecol. 2010; 203(6): 547.e1-10. doi: 10.1016/j.ajog.2010.07.037
  9. Gallos I.D., Krishan P., Shehmar M., Ganesan R., Gupta J.K. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod. 2013; 28(11): 2966-71. doi: 10.1093/humrep/det320
  10. Клинышкова Т.В., Фролова Н.Б., Мозговой С.И. Клинико-морфологическое обоснование оптимизации лечения больных с гиперплазией эндометрия. Российский вестник акушера-гинеколога. 2010; 3: 16-20.
  11. Чернуха Г.Е., Могиревская О.А., Шигорева Т.В., Грибанова Н.Д. Клиникоморфологические аспекты внутриматочного воздействия левоноргестрела при гиперплазии эндометрия. Акушерство и гинекология. 2011; 4: 56-62.
  12. Management of Endometrial Hyperplasia. Green-top Guideline No. 67 RCOG/BSGE Joint Guideline | February 2016 https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf
  13. rbo A., Arnes M., Vereide A.B., Straume B. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG. 2016;123(9):1512-9. doi: 10.1111/ 1471-0528.13763.
  14. Тихомиров А.Л. Обоснование использования комбинированных оральных контрацептивов для профилактики рецидивов типичных гиперплазий эндометрия. Гинекология. 2018; 20(4): 26-8.
  15. Гиперпластические процессы эндометрия. Гинекология. Национальное руководство. М., 2017. С. 303-308. [Hyperplastic processes of the endometrium. Gynecology. National leadership. M., 2017; 303-308. (in Russian)]

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2020